|
|
Article: New proteinuria study findings reported from National University.
- Article from:
- Cancer Weekly
- Article date:
- November 10, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
In this recent report, researchers in Singapore, Singapore conducted a study "To determine the safety and tolerability of ABT-869 at escalating doses and its effects on biomarkers relevant for antiangiogenic activity in patients with solid malignancies. Patients with solid malignancies refractory to or for which no standard effective therapy exists were enrolled onto escalating-dose cohorts and treated with oral ABT-869 once daily continuously."
"Thirty-three patients were studied at doses of 10 mg/d, 0.1 mg/kg/d, 0.25 mg/kg/d, and 0.3 mg/kg/d. Dose-limiting toxicities in the first cycle (21 days) included grade 3 fatigue in a patient at 10 mg/d, grade 3 ...
Related newspaper, magazine, and journal articles:
|
|
Article: Studies from Seoul National University, Department ...
Cancer Weekly;
March 10, 2009 ;
700+ words
... ... Japanese Journal of Clinical Oncology (Metastatic adrenocortical ... Japanese Journal of Clinical Oncology, 2009;39(3 ... O. Lee, Seoul National University Bundang Hospital ... Japanese Journal of Clinical Oncology can be contacted ...
|
|